6.6486
price down icon3.22%   -0.1914
 
loading
Mind Medicine Inc stock is traded at $6.6486, with a volume of 458.28K. It is down -3.22% in the last 24 hours and down -18.97% over the past month. Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
See More
Previous Close:
$6.84
Open:
$6.6
24h Volume:
458.28K
Relative Volume:
0.40
Market Cap:
$476.11M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.341
EPS:
-1.99
Net Cash Flow:
$-64.37M
1W Performance:
-6.50%
1M Performance:
-18.97%
6M Performance:
-8.18%
1Y Performance:
+80.87%
1-Day Range:
Value
$6.40
$6.67
1-Week Range:
Value
$6.40
$7.8699
52-Week Range:
Value
$3.49
$12.22

Mind Medicine Inc Stock (MNMD) Company Profile

Name
Name
Mind Medicine Inc
Name
Phone
212-220-6633
Name
Address
ONE WORLD TRADE CENTER, NEW YORK
Name
Employee
57
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MNMD's Discussions on Twitter

Compare MNMD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MNMD
Mind Medicine Inc
6.65 476.11M 11.40B -95.73M -64.37M -2.45
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
401.74 103.35B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
703.95 77.35B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
621.19 37.04B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.28 30.14B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
112.54 26.97B 3.30B -501.07M 1.03B -2.1146

Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-24 Initiated Chardan Capital Markets Buy
Oct-14-24 Resumed Leerink Partners Outperform
Jul-24-24 Initiated ROTH MKM Buy
May-29-24 Initiated Robert W. Baird Outperform
Apr-15-24 Initiated Leerink Partners Outperform
Dec-05-23 Initiated Canaccord Genuity Buy
Dec-09-22 Resumed ROTH Capital Buy
Nov-16-22 Initiated RBC Capital Mkts Outperform
Aug-26-22 Initiated Oppenheimer Outperform
Aug-10-22 Initiated Cantor Fitzgerald Overweight
May-04-22 Initiated ROTH Capital Buy
Jun-28-21 Initiated Maxim Group Buy
View All

Mind Medicine Inc Stock (MNMD) Latest News

pulisher
Dec 29, 2024

(MNMD) Investment Analysis - Stock Traders Daily

Dec 29, 2024
pulisher
Dec 28, 2024

Mind Medicine's chief medical officer sells shares worth $49,357 - Investing.com India

Dec 28, 2024
pulisher
Dec 28, 2024

Mind Medicine's chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Australia

Dec 28, 2024
pulisher
Dec 27, 2024

Mind Medicine CEO Robert Barrow sells shares worth $141,957 By Investing.com - Investing.com Nigeria

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine's chief legal officer sells $33,576 in stock - Investing.com India

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine CEO Robert Barrow sells shares worth $141,957 - Investing.com India

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Insider Sells $49,357.49 in Stock - MarketBeat

Dec 27, 2024
pulisher
Dec 27, 2024

Carrie Liao Sells 2,273 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock - MarketBeat

Dec 27, 2024
pulisher
Dec 27, 2024

Mind medicine's chief accounting officer sells shares for $16,888 By Investing.com - Investing.com Canada

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine’s chief medical officer sells shares worth $49,357 By Investing.com - Investing.com Nigeria

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine's chief legal officer sells $33,576 in stock By Investing.com - Investing.com South Africa

Dec 27, 2024
pulisher
Dec 27, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 8.5%Here's Why - MarketBeat

Dec 27, 2024
pulisher
Dec 26, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap DownHere's Why - MarketBeat

Dec 26, 2024
pulisher
Dec 25, 2024

MindMed Stock Skyrockets 94% Year to Date: What's Driving It? - MSN

Dec 25, 2024
pulisher
Dec 24, 2024

MindMed Stock Skyrockets 94% Year To Date: What's Driving It? - Barchart

Dec 24, 2024
pulisher
Dec 23, 2024

5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance

Dec 23, 2024
pulisher
Dec 20, 2024

Chardan Capital Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation - MSN

Dec 20, 2024
pulisher
Dec 20, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Chardan Capital - MarketBeat

Dec 20, 2024
pulisher
Dec 20, 2024

Wellington Management Group LLP Purchases 109,152 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat

Dec 20, 2024
pulisher
Dec 19, 2024

MindMed joins Nasdaq Biotechnology Index - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

MindMed to Be Added to the Nasdaq Biotechnology Index - Business Wire

Dec 19, 2024
pulisher
Dec 19, 2024

MindMed Joins Nasdaq Biotech Index After Landmark Year of $250M Funding and Clinical Advances - StockTitan

Dec 19, 2024
pulisher
Dec 19, 2024

Objective long/short (MNMD) Report - Stock Traders Daily

Dec 19, 2024
pulisher
Dec 18, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 4.9% HigherStill a Buy? - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Receives "Outperform" Rating from Oppenheimer - MarketBeat

Dec 17, 2024
pulisher
Dec 17, 2024

MindMed doses first subject in trial of tablets for generalised anxiety disorder - Yahoo Finance

Dec 17, 2024
pulisher
Dec 16, 2024

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - newsbreak.com

Dec 16, 2024
pulisher
Dec 16, 2024

Brokerages Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Price Target at $27.71 - MarketBeat

Dec 16, 2024
pulisher
Dec 15, 2024

Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 15, 2024

Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment - Investing.com India

Dec 15, 2024
pulisher
Dec 11, 2024

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress - Business Wire

Dec 11, 2024
pulisher
Dec 08, 2024

Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily

Dec 08, 2024
pulisher
Dec 07, 2024

MindMed awarded Innovation Passport for MM120 - The Pharma Letter

Dec 07, 2024
pulisher
Dec 05, 2024

Insider Buying: David Gryska Acquires Additional Shares of Mind Medicine Inc (MNMD) - GuruFocus.com

Dec 05, 2024
pulisher
Dec 05, 2024

Mind Medicine director David Gryska acquires $17,925 in shares - Investing.com

Dec 05, 2024
pulisher
Dec 05, 2024

Mind Medicine director David Gryska acquires $17,925 in shares By Investing.com - Investing.com Nigeria

Dec 05, 2024
pulisher
Dec 05, 2024

MindMed gains UK Innovation Passport for GAD treatment - Investing.com

Dec 05, 2024
pulisher
Dec 05, 2024

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) - Business Wire

Dec 05, 2024
pulisher
Dec 03, 2024

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - citybiz

Dec 03, 2024
pulisher
Dec 03, 2024

MindMed appoints new VP of R&D Strategy - Investing.com

Dec 03, 2024
pulisher
Dec 03, 2024

MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK

Dec 03, 2024
pulisher
Dec 02, 2024

MindMed Announces New Employee Inducement Grants - Business Wire

Dec 02, 2024
pulisher
Nov 30, 2024

Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat

Nov 30, 2024
pulisher
Nov 28, 2024

Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat

Nov 28, 2024
pulisher
Nov 26, 2024

Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 26, 2024
pulisher
Nov 25, 2024

MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com

Nov 25, 2024
pulisher
Nov 22, 2024

Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat

Nov 22, 2024
pulisher
Nov 21, 2024

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat

Nov 21, 2024
pulisher
Nov 19, 2024

Generalized Anxiety Disorder Market to Reach New Heights - openPR

Nov 19, 2024
pulisher
Nov 19, 2024

MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter

Nov 19, 2024
pulisher
Nov 19, 2024

Vera hires Jason Carter as chief legal officer - BioCentury

Nov 19, 2024

Mind Medicine Inc Stock (MNMD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Mind Medicine Inc Stock (MNMD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Liao Carrie
Chief Accounting Officer
Dec 26 '24
Sale
7.43
2,273
16,888
97,270
Karlin Dan
Chief Medical Officer
Dec 26 '24
Sale
7.43
6,643
49,357
338,013
Sullivan Mark
Chief Legal Officer
Dec 26 '24
Sale
7.43
4,519
33,576
173,197
$68.46
price down icon 1.17%
$20.80
price down icon 1.07%
$38.96
price down icon 2.72%
$355.76
price down icon 1.11%
$181.94
price down icon 0.21%
$112.40
price down icon 1.39%
Cap:     |  Volume (24h):